🌍 Worldwide🎗️ Cancer & Oncology📡 OpenAlex🕒 Updated November 2, 2026

Most-Cited Antibody-Drug Conjugates Papers This Year (2026)

As of November 2, 2026, “Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer” leads Most-Cited Antibody-Drug Conjugates Papers This Year with 132 citations. “HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial” is second and “Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer” third.

WhatsApp Telegram X Facebook ⓘ Methodology

🚫 No paid placement📡 Source: OpenAlex🕒 Updated November 2, 2026 ⓘ How we measure

🎗️2

HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trialJianchun Duan et al. · Cancer Cell · 2026-03-0525 citations

👑

🎗️1

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder CancerChristof Vulsteke et al. · New England Journal of Medicine · 2026-02-18132 citations

🎗️3

Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast CancerDileep Reddy Rampa et al. · Clinical Cancer Research · 2026-01-2720 citations

Full ranking

🎗️

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer ↗ •🏆 Leader

Christof Vulsteke et al. · New England Journal of Medicine · 2026-02-18

132 citationsCitations

🎗️

HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial ↗ •

Jianchun Duan et al. · Cancer Cell · 2026-03-05

25 citationsCitations

🎗️

Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer ↗ •

Dileep Reddy Rampa et al. · Clinical Cancer Research · 2026-01-27

20 citationsCitations

🎗️

Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial ↗ •

Anwen Xiong et al. · The Lancet · 2026-05-29

15 citationsCitations

🎗️

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy ↗ •

Yangyang Li et al. · Medicine Bulletin · 2026-01-01

14 citationsCitations

🎗️

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD ↗ •

Jonathan Wesley Riess et al. · Annals of Oncology · 2026-03-02

13 citationsCitations

🎗️

CA9+ cancer-associated fibroblasts cooperate with SPP1+ tumor-associated macrophages driving immune resistance in triple-negative breast cancer ↗ •

Qin Ma et al. · Cellular and Molecular Life Sciences · 2026-01-09

13 citationsCitations

🎗️

Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial ↗ •

Melissa Lynne Johnson et al. · The Lancet Oncology · 2026-03-31

12 citationsCitations

🎗️

Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer ↗ •

Yuzhao Wang et al. · Cancer Cell · 2026-05-21

11 citationsCitations

🎗️

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study ↗ •

David Planchard et al. · Cancer Cell · 2026-04-17

11 citationsCitations

How this ranking works

Ranked by citation count (OpenAlex) among research papers published this year whose title or abstract matches this topic. Citations build up over time, so the newest papers rank lower. For information only, not medical advice.

Methodology →

SourceOpenAlex

SignalCitations

Last updatedNov 2, 2026, 4:27 PM UTC

Top 10Citations of papers published this year